Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inolimomab (OPi).

Michael Winkler1

  • 1Klinik für Visceral- und Transplantationschirurgie, Transplantationschirurgie, Medizinische Hochschule Hannover, Germany. Winkler.Michael@mh-Hannover.de

Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4.

Journal of virology·2026
Same author

Development of immortalized Callithrix jacchus kidney cell lines supporting infection with a panel of viruses.

PloS one·2026
Same author

A Rare Case of Uterine Rupture in the First Trimester of Pregnancy Secondary to Placenta Accreta Spectrum.

Clinical case reports·2025
Same author

Embryonic transcripts in heart failure: Time for reprogrammed thinking?

European journal of heart failure·2025
Same author

Neutralizing activity against bovine H5N1 HPAIV (clade 2.3.4.4b) in human plasma after seasonal influenza vaccination.

Emerging microbes & infections·2025
Same author

Genetic Exploration of Targeting the Transient Receptor Potential Cation Channel Subfamily Member 6.

Journal of cardiovascular pharmacology·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Inolimomab, an anti-interleukin-2 receptor antibody, is being investigated for treating acute graft versus host disease. Clinical trials are ongoing to evaluate its efficacy and safety in patients.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Acute graft versus host disease (GvHD) is a serious complication following allogeneic stem cell transplantation.
  • The interleukin-2 receptor (CD25) plays a critical role in T-cell activation, making it a target for immunosuppression in GvHD.

Purpose of the Study:

  • To evaluate the efficacy and safety of inolimomab, a monoclonal antibody targeting CD25, for the treatment of acute GvHD.

Main Methods:

  • Inolimomab, an anti-CD25 monoclonal antibody developed by OPi (Orphan Pharma International), was assessed in clinical trials.
  • The study involved patients with acute GvHD, with trials progressing through Phase II/III stages as of April 2001.

Main Results:

  • Data on the efficacy and safety of inolimomab in treating acute GvHD were being collected during Phase II/III clinical trials.

Related Experiment Videos

  • The trials aimed to determine the therapeutic potential of targeting the interleukin-2 receptor in this patient population.

    • Conclusions:

    • Inolimomab shows promise as a potential therapeutic agent for acute GvHD by targeting the CD25 receptor.
    • Further clinical evaluation is necessary to confirm its role in managing this post-transplant complication.